Abstract：【Objective】 To study the effects of Tripterygium wilfordii multi glucoside tablets on the treatment of elderly IgA nephropathy and its effects on plasminogen activator inhibitor type-1 (PAI-1),Transforming growth factor beta 1 (TGF-β1). 【Methods】According to lottery drawing method, 90 elderly patients of IgA nephropathy were divided into two group, with 45 cases in each. Patients in the control group received routine treatment, while patients in the observation group were treated with glycosides of Tripterygium wilfordii (20mg each time with 3 times a day) in addition to routine treatment of the control group. The two groups were treated for one year. Afterwards, the therapeutic efficacy-levels of urinary protein, SCr (serum creatinine), Alb (plasma albumin) BUN (serum urea nitrogen), PAI-1, and TGF- beta 1-were compared between the two groups. 【Results】 The total effective rate of the observation group was significantly higher than that of the control group(P＜0.05). The levels of urine protein content, SCr, BUN, PAI-1 and TGF- beta 1 in the observation group were significantly lower than those in the control group(P＜0.05). The level of Alb of the observation group was significantly higher than that of the control group(P＜0.05); There was no significant difference in adverse reactions between the two groups (P>0.05). 【Conclusion】Glycosides of Tripterygium wilfordii is effective for treatment of elderly IgA nephropathy. It can improve renal function, reduce urinary protein, delay disease progression and decrease the expression of PAI-1 and TGF- beta 1.
党同光, 韩超, 王翠, 刘合国, 张莉莉, 田景友. 雷公藤多苷片治疗老年IgA肾病的疗效及对PAI-1、TGF-β1的影响[J]. 医学临床研究, 2018, 35(6): 1113-1114.
DANG Tong-guang, HAN Chao, WANG Cui, et al. Effect of Tripterygium Wilfordii Multi Glucoside Tablets on the Treatment of Elderly IgA Nephropathy and Its Effect on PAI-1 and TGF- beta 1. JOURNAL OF CLINICAL RESEARCH, 2018, 35(6): 1113-1114.
[1] 张颖慧,石红光,陈舟,等.雷公藤多苷联合小剂量糖皮质激素对IgA肾病伴肾功能减退患者的疗效观察[J].中国中西医结合肾病杂志,2014,15(04):341-343.
[2] 何川鄂,朱平,杨芦蓉, 等.临床表现为肾病综合征的IgA肾病临床分析及治疗效果[J].广东医学,2014,35(16):2586-2589.
[3] Wu C, Li G, Wang L. The interaction effect of rs4077515 and rs17019602 increases the susceptibility to IgA nephropathy[J]. Oncotarget,2017,8(44):76492-76497.
[4] 黄兰,赵亚娟,刘艳红,等. 老年IgA肾病临床病理特点分析[J]. 中国老年学, 2013 , 33 (11) :2692-2693.
[5] 项琼,宋恩峰,刘红燕.雷公藤多苷片联合替米沙坦治疗中老年IgA肾病患者疗效观察[J].世界中西医结合杂志,2014,9(07):756-758.
[6] Duan ZY, Cai GY, Li JJ, et al. Urinary Erythrocyte-Derived miRNAs: Emerging Role in IgA Nephropathy[J]. Kidney Blood Press Res,2017,42(4):738-748.
[7] 张慧儒.雷公藤多苷联合吗替麦考酚酯治疗老年IgA肾病的疗效观察[J].中国医药导报,2013,10(01):81-82.
[8] 张连云,化秋菊,刘向东,等. IgA肾病的临床病理特征及激素疗效观察[J]. 医学临床研究,2016,33(4):698-700.
[9] Yang M, Xie J, Ouyang Y, et al. ABO blood type is associated with renal outcomes in patients with IgA nephropathy[J]. Oncotarget,2017,8(43):73603-73612.
2018, Vol. 35 
